SG11201907695WA - Product and method for the treatment of bioprosthetic tissues - Google Patents

Product and method for the treatment of bioprosthetic tissues

Info

Publication number
SG11201907695WA
SG11201907695WA SG11201907695WA SG11201907695WA SG11201907695WA SG 11201907695W A SG11201907695W A SG 11201907695WA SG 11201907695W A SG11201907695W A SG 11201907695WA SG 11201907695W A SG11201907695W A SG 11201907695WA SG 11201907695W A SG11201907695W A SG 11201907695WA
Authority
SG
Singapore
Prior art keywords
international
pct
treatment
rue
english
Prior art date
Application number
SG11201907695WA
Inventor
Enrico Pasquino
Marcio Scorsin
Original Assignee
Epygon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epygon filed Critical Epygon
Publication of SG11201907695WA publication Critical patent/SG11201907695WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/042—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3625—Vascular tissue, e.g. heart valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/02—Treatment of implants to prevent calcification or mineralisation in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/20—Materials or treatment for tissue regeneration for reconstruction of the heart, e.g. heart valves

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 30 August 2018 (30.08.2018) WIP0 I PCT oimiolollm °nolo °H0111 m onno (10) International Publication Number WO 2018/153525 Al (51) International Patent Classification: A61L 31/04 (2006.01) (21) International Application Number: PCT/EP2017/080977 (22) International Filing Date: 30 November 2017 (30.11.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17157490.8 22 February 2017 (22.02.2017) EP (71) Applicant: EPYGON [FR/FR]; 5 rue de la Baume, 75008 Paris (FR). (72) Inventors: PASQUINO, Enrico; Route de la Roche 4, 1073 Savigny (CH). SCORSIN, Marcio; 18, Rue de Nas- sau, 2213 Luxembourg (LU). (74) Agent: GROSFILLIER, Philippe; c/o Andre Roland SA, P.O Box 5107, 1002 Lausanne (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). — Published: with international search report (Art. 21(3)) 00 1-1 (54) Title: PRODUCT AND METHOD FOR THE TREATMENT OF BIOPROSTHETIC TISSUES O \" (57) : The invention concerns the treatment of bioprosthetic tissues a Cyclodextrin, preferably in association with Ethanol. C
SG11201907695WA 2017-02-22 2017-11-30 Product and method for the treatment of bioprosthetic tissues SG11201907695WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17157490.8A EP3366324A1 (en) 2017-02-22 2017-02-22 Product and method for the treatment of bioprosthetic tissues
PCT/EP2017/080977 WO2018153525A1 (en) 2017-02-22 2017-11-30 Product and method for the treatment of bioprosthetic tissues

Publications (1)

Publication Number Publication Date
SG11201907695WA true SG11201907695WA (en) 2019-09-27

Family

ID=58108558

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907695WA SG11201907695WA (en) 2017-02-22 2017-11-30 Product and method for the treatment of bioprosthetic tissues

Country Status (13)

Country Link
US (1) US11660375B2 (en)
EP (2) EP3366324A1 (en)
JP (1) JP2020508193A (en)
KR (1) KR20190121326A (en)
CN (1) CN110494171A (en)
AU (1) AU2017400910B2 (en)
BR (1) BR112019017295A2 (en)
CA (1) CA3054091A1 (en)
ES (1) ES2936112T3 (en)
IL (1) IL268865A (en)
RU (1) RU2019127523A (en)
SG (1) SG11201907695WA (en)
WO (1) WO2018153525A1 (en)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55159760A (en) * 1979-06-01 1980-12-12 Sugiyama Sangyo Kagaku Kenkyusho Healthy food
JPS57186463A (en) * 1981-05-08 1982-11-16 Nisshin Oil Mills Ltd:The Production of mayonnaise-like acidic emulsion food product
JP3495082B2 (en) * 1994-04-13 2004-02-09 財団法人糧食研究会 How to collect cholesterol
US5931969A (en) 1994-07-29 1999-08-03 Baxter International Inc. Methods and apparatuses for treating biological tissue to mitigate calcification
JPH08173060A (en) * 1994-12-28 1996-07-09 Q P Corp Cholesterol-removing method in cholesterol-containing liquid food
WO2002043778A2 (en) * 2000-11-01 2002-06-06 Edwards Lifesciences Corporation Methods for preparation of bioprosthetic tissue and implantable devices comprising such bioprosthetic tissue
US7989157B2 (en) * 2005-01-11 2011-08-02 Medtronic, Inc. Solution for storing bioprosthetic tissue used in a biological prosthesis
US7579381B2 (en) * 2005-03-25 2009-08-25 Edwards Lifesciences Corporation Treatment of bioprosthetic tissues to mitigate post implantation calcification
CN101161293A (en) * 2006-10-12 2008-04-16 胡盛寿 Resist calcification modified method of heterogeneity biological organization material
US8357387B2 (en) * 2007-12-21 2013-01-22 Edwards Lifesciences Corporation Capping bioprosthetic tissue to reduce calcification
CA2860829C (en) * 2011-12-13 2016-08-16 Boston Scientific Scimed, Inc. Decalcifying heart valve
EP2712633B1 (en) * 2012-10-02 2015-04-29 Biotronik AG Bioprosthetic components for an implant, in particular partly crosslinked biological heart valves
CN106190949B (en) * 2015-05-08 2020-04-10 上海微创心通医疗科技有限公司 Dry animal-derived collagen fiber tissue material, preparation method thereof and bioprosthesis

Also Published As

Publication number Publication date
CN110494171A (en) 2019-11-22
EP3585451B1 (en) 2022-10-19
BR112019017295A2 (en) 2020-03-31
RU2019127523A (en) 2021-03-23
IL268865A (en) 2019-10-31
WO2018153525A1 (en) 2018-08-30
US11660375B2 (en) 2023-05-30
AU2017400910A1 (en) 2019-09-12
AU2017400910B2 (en) 2023-10-12
EP3585451A1 (en) 2020-01-01
CA3054091A1 (en) 2018-08-30
ES2936112T3 (en) 2023-03-14
KR20190121326A (en) 2019-10-25
EP3366324A1 (en) 2018-08-29
JP2020508193A (en) 2020-03-19
RU2019127523A3 (en) 2021-03-23
US20210213169A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201805507UA (en) Retractable heat source for aerosol generating article
SG11201811184UA (en) Lag -3 binding members
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201903153PA (en) Metal recovery process
SG11201808476SA (en) Recycling of polymer matrix composite
SG11201907948TA (en) Formulations comprising pd-1 binding proteins and methods of making thereof
SG11201805001UA (en) Method of treating influenza a
SG11201907774VA (en) Sulfoximine glycosidase inhibitors
SG11201808829VA (en) Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease
SG11201807949WA (en) Engineered immunoglobulins with altered fcrn binding
SG11201906778RA (en) Improved methods for assessing risk of developing breast cancer
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201900336YA (en) Radioligands for imaging the ido1 enzyme
SG11201805263TA (en) Compositions and methods for detecting and treating esophageal cancer
SG11201906313SA (en) A polypeptide linker for preparing multispecific antibodies
SG11201809671PA (en) Imidazolone compounds as human neutrophil elastase inhibitors
SG11201810123SA (en) Treatment of intrahepatic cholestatic diseases
SG11201805141QA (en) Compositions and methods for detecting and treating gastric cancer
SG11201809551TA (en) Selection of bacterial strains useful in allergy treatment
SG11201908888VA (en) Compositions and methods for treating lung cancer
SG11201809541UA (en) Immune checkpoint inhibitors and cytotoxic t cells for the treatment of cancer